{
    "id": 80146,
    "name": "childhood B-cell acute lymphoblastic leukemia",
    "source": "DOID",
    "definition": "A childhood acute lymphoblastic leukemia that has_material_basis in B-cells. [url:https\\://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&version=16.07d&ns=NCI_Thesaurus&code=C9140]",
    "currentPreferredTerm": null,
    "lastUpdateDateFromDO": "03/24/2020",
    "altIds": [
        
    ],
    "termId": "DOID:0080146",
    "evidence": [
        {
            "id": 11417,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (ELIANA) that supported FDA approval, Kymriah (tisagenlecleucel) treatment led to complete remission or complete remission with incomplete blood count recovery in 83% (52/63) of pediatric and young adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia (22nd Congress of EHA, June 2017, Abstract S476; NCT02435849).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 5981,
                "therapyName": "Tisagenlecleucel",
                "synonyms": null
            },
            "indication": {
                "id": 80146,
                "name": "childhood B-cell acute lymphoblastic leukemia",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 9302,
                    "pubMedId": null,
                    "title": "Patient-reported quality of life (QOL) following CTL019 in pediatric and young adult patients (pts) with relapsed/refractory (r/r) b-cell acute lymphoblastic leukemia (B-ALL).",
                    "url": "http://abstracts.asco.org/199/AbstView_199_187018.html"
                },
                {
                    "id": 9824,
                    "pubMedId": null,
                    "title": "Analysis of a Global Registration Trial of the Efficacy and Safety of CTL019 in Pediatric and Young Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL)",
                    "url": "http://www.bloodjournal.org/content/128/22/221"
                },
                {
                    "id": 11312,
                    "pubMedId": null,
                    "title": "GLOBAL REGISTRATION TRIAL OF EFFICACY AND SAFETY OF CTL019 IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH RELAPSED/REFRACTORY (R/R) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL): UPDATE TO THE INTERIM ANALYSIS",
                    "url": "https://learningcenter.ehaweb.org/eha/2017/22nd/181763/stephan.a.grupp.global.registration.trial.of.efficacy.and.safety.of.ctl019.in.html?f=menu=6*ce_id=1181*ot_id=16875*media=3"
                },
                {
                    "id": 15673,
                    "pubMedId": null,
                    "title": "Kymriah (tisagenlecleucel) FDA Drug Label",
                    "url": "https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/kymriah-tisagenlecleucel"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 15037,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, bone marrow mononuclear cells from a pediatric B-cell acute lymphoblastic leukemia with an acquired Jak2 R938Q mutation were resistant to Jakafi (ruxolitinib) (PMID: 29025600).",
            "molecularProfile": {
                "id": 30692,
                "profileName": "JAK2 R938Q"
            },
            "therapy": {
                "id": 907,
                "therapyName": "Ruxolitinib",
                "synonyms": null
            },
            "indication": {
                "id": 80146,
                "name": "childhood B-cell acute lymphoblastic leukemia",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 12520,
                    "pubMedId": 29025600,
                    "title": "A novel somatic JAK2 kinase-domain mutation in pediatric acute lymphoblastic leukemia with rapid on-treatment development of LOH.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29025600"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15410,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Gleevec (imatinib mesylate) treatment resulted in remission greater than eleven years in a pediatric patient with refractory B-cell precursor acute lymphoblastic leukemia harboring an RCSD1-ABL1 fusion (PMID: 27125982).",
            "molecularProfile": {
                "id": 31012,
                "profileName": "RCSD1 - ABL1"
            },
            "therapy": {
                "id": 770,
                "therapyName": "Imatinib",
                "synonyms": null
            },
            "indication": {
                "id": 80146,
                "name": "childhood B-cell acute lymphoblastic leukemia",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 13168,
                    "pubMedId": 27125982,
                    "title": "Imatinib-induced long-term remission in a relapsed RCSD1-ABL1-positive acute lymphoblastic leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27125982"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "clinicalTrials": [
        {
            "nctId": "NCT02228096",
            "title": "Study of Efficacy and Safety of CTL019 in Pediatric ALL Patients",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 5981,
                    "therapyName": "Tisagenlecleucel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02435849",
            "title": "Determine Efficacy and Safety of CTL019 in Pediatric Patients With Relapsed and Refractory B-cell ALL (ELIANA)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5981,
                    "therapyName": "Tisagenlecleucel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02808442",
            "title": "Study of UCART19 in Pediatric Patients With Relapsed/Refractory B Acute Lymphoblastic Leukemia (PALL)",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 5997,
                    "therapyName": "UCART19",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02877303",
            "title": "Blinatumomab and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9108,
                    "therapyName": "Blinatumomab + Cyclophosphamide + Dexamethasone + Doxorubicin + Vincristine",
                    "synonyms": null
                },
                {
                    "id": 9109,
                    "therapyName": "Blinatumomab + Mercaptopurine + Methotrexate + Prednisone + Vincristine",
                    "synonyms": null
                },
                {
                    "id": 9110,
                    "therapyName": "Cyclophosphamide + Cytarabine + Dexamethasone + Doxorubicin + Methotrexate + Vincristine",
                    "synonyms": null
                },
                {
                    "id": 9111,
                    "therapyName": "Cyclophosphamide + Cytarabine + Dexamethasone + Doxorubicin + Methotrexate + Ofatumumab + Vincristine",
                    "synonyms": null
                },
                {
                    "id": 9112,
                    "therapyName": "Cyclophosphamide + Cytarabine + Dexamethasone + Doxorubicin + Methotrexate + Rituximab + Vincristine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02981628",
            "title": "Inotuzumab Ozogamicin in Treating Younger Patients With Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia",
            "phase": "Phase II",
            "recruitment": "Suspended",
            "therapies": [
                {
                    "id": 3199,
                    "therapyName": "inotuzumab ozogamicin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03123939",
            "title": "Expanded Treatment Protocol in Acute Lymphoblastic Leukemia",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 5981,
                    "therapyName": "Tisagenlecleucel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03595917",
            "title": "ABL001 + Dasatinib + Prednisone in BCR-ABL+ B-ALL or CML",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5561,
                    "therapyName": "Asciminib + Dasatinib + Prednisone",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03605589",
            "title": "Pembro + Blina Combination in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Leukemia or Lymphoma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5839,
                    "therapyName": "Blinatumomab + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03642626",
            "title": "MT2017-45: CAR-T Cell Therapy for Heme Malignancies",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7940,
                    "therapyName": "Cyclophosphamide + Fludarabine + Tisagenlecleucel",
                    "synonyms": null
                },
                {
                    "id": 5098,
                    "therapyName": "Cyclophosphamide + Fludarabine + KTE-C19",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03876769",
            "title": "Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients (CASSIOPEIA)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5981,
                    "therapyName": "Tisagenlecleucel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03913559",
            "title": "Inotuzumab Ozogamicin for Children With MRD Positive CD22+ Lymphoblastic Leukemia",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 3199,
                    "therapyName": "inotuzumab ozogamicin",
                    "synonyms": null
                },
                {
                    "id": 8175,
                    "therapyName": "Cytarabine + Hydrocortisone + Methotrexate",
                    "synonyms": null
                },
                {
                    "id": 8161,
                    "therapyName": "Acetaminophen + Diphenhydramine + Methylprednisolone",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03959085",
            "title": "Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy",
            "phase": "Phase III",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8550,
                    "therapyName": "Dexamethasone + Doxorubicin + Methotrexate + Pegaspargase + Vincristine",
                    "synonyms": null
                },
                {
                    "id": 8555,
                    "therapyName": "Cyclophosphamide + Cytarabine + Mercaptopurine + Methotrexate + Pegaspargase + Vincristine",
                    "synonyms": null
                },
                {
                    "id": 8542,
                    "therapyName": "Leucovorin + Mercaptopurine + Methotrexate + Vincristine",
                    "synonyms": null
                },
                {
                    "id": 3199,
                    "therapyName": "inotuzumab ozogamicin",
                    "synonyms": null
                },
                {
                    "id": 8735,
                    "therapyName": "Cytarabine + Daunorubicin + Dexamethasone + Methotrexate + Pegaspargase + Vincristine",
                    "synonyms": null
                },
                {
                    "id": 8736,
                    "therapyName": "Cytarabine + Daunorubicin + Methotrexate + Pegaspargase + Prednisolone + Vincristine",
                    "synonyms": null
                },
                {
                    "id": 8737,
                    "therapyName": "Cyclophosphamide + Cytarabine + Methotrexate + Pegaspargase + Thioguanine + Vincristine",
                    "synonyms": null
                },
                {
                    "id": 8738,
                    "therapyName": "inotuzumab ozogamicin + Methotrexate",
                    "synonyms": null
                },
                {
                    "id": 8547,
                    "therapyName": "Methotrexate + Pegaspargase + Vincristine",
                    "synonyms": null
                },
                {
                    "id": 8548,
                    "therapyName": "Mercaptopurine + Methotrexate + Prednisolone + Vincristine",
                    "synonyms": null
                }
            ]
        }
    ]
}